Cargando…
RNA Technologies in Cardiovascular Medicine and Research
Cardiovascular disease is the number one cause of death worldwide. In 2005 17.5 million people, representing 30% of all global deaths, died of cardiovascular disease. For this reason every effort needs to be made to improve the early diagnosis and treatment procedures for combating this disease. Thi...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor Corporativo: | |
| Otros Autores: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Berlin, Heidelberg :
Springer Berlin Heidelberg : Imprint: Springer,
2008.
|
| Edición: | 1st ed. 2008. |
| Temas: | |
| Acceso en línea: | Texto Completo |
Tabla de Contenidos:
- MicroRNA
- An Overview of MicroRNA
- MicroRNAs and Their Potential
- miRNAs and Their Emerging Role in Cardiac Hypertrophy
- MicroRNAs and the Control of Heart Pathophysiology
- MicroRNA Systems Biology
- RNA Interference
- Targeting Viral Heart Disease by RNA Interference
- Design of siRNAs and shRNAs for RNA Interference: Possible Clinical Applications
- RNA Interference and MicroRNA Modulation for the Treatment of Cardiac Disorders
- Cardiac Delivery of Nucleic Acids by Transcriptional and Transductional Targeting of Adeno-Associated Viral Vectors
- Ribozymes
- Characterization of Hammerhead Ribozymes Potentially Suitable for the Treatment of Hyper-Proliferative Vascular Diseases
- Applications of Ribozymes and Pyrrole-Imidazole Polyamides for Cardiovascular and Renal Diseases
- Noncoding, Aptamer and Antisense RNAs
- Noncoding RNAs in Human Diseases
- Aptamers and siRNAs in Cardiovascular Disease
- Nucleic Acid Aptamers for Cardiovascular Therapeutics
- NF?B Decoy Oligodeoxynucleotide-Based Therapy in Cardiovascular Diseases
- Antisense Therapy for Restenosis Following Percutaneous Coronary Interventions
- Toxic RNA in Pathogenesis of Human Neuromuscular Disorders.